{"organizations": ["NantKwest", "IPO NantKwest"], "uuid": "af3538fcd7336da3c6ed21a4b37f1cf3610dec4b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530497?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "NantKwest nets $197mm in IPO", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "NantKwest nets $197mm in IPO", "spam_score": 0.0, "site_type": "news", "published": "2015-07-30T19:46:00.000+03:00", "replies_count": 0, "uuid": "af3538fcd7336da3c6ed21a4b37f1cf3610dec4b"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530497?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "NantKwest nets $197mm in IPO", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "NantKwest nets $197mm in IPO Deal Date: Jul-01-2015 / Deal # 201530497 Executive Summary \nNantKwest Inc (formerly Conkwest; natural killer (NK) cells for cancer, infectious disease, and immune disorders) netted $197mm in its IPO of 8.3mm shares at $25, above its planned terms of 7mm shares for $20-23. Existing stockholders including Franklin Templeton and NantKwest CEO Patrick Soon-Shiong, MD, agreed to buy $55.5mm in IPO shares. In a separate private placement, NantKwest raised $17mm from Celgene .", "external_links": [], "published": "2015-07-30T19:46:00.000+03:00", "crawled": "2015-07-31T14:40:08.845+03:00", "highlightTitle": ""}